News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ark Therapeutics to License Out Heart Attack Risk Kit Marketing
October 8, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 8 (Reuters) - Ark Therapeutics (AKT.L: Quote, Profile, Research) said on Monday it was to license out marketing rights for its Ox-LDL heart attack risk test kit to UK-based diagnostics company Lab21.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
IPOs
UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio
October 7, 2025
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Pfizer Beat Out Two Other Metsera Suitors for Takeover
October 7, 2025
·
3 min read
·
Tristan Manalac
Drug pricing
Amgen Hops on DTC Train To Offer Repatha at 60% Discount
October 7, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Most Life Sciences Companies Not Planning New Investments After Tariffs: Report
October 7, 2025
·
3 min read
·
Dan Samorodnitsky
